Details of Disease

General Information of Disease (ID: DISQ8RM8)

Disease Name	Migraine
Synonyms	Mgr1; migraine; Mgau; migraine, susceptibility to; migraine with or without aura, susceptibility to, type 1; migraine without aura, susceptibility to; migraine with or without aura, susceptibility to, 1; migraine, resistance to
Disease Class	8A80: Migraine
Disease Hierarchy	DISHW5IK: Migraine with or without aura, susceptibility to DISQ8RM8: Migraine
ICD Code	ICD-11 ICD-11: 8A80 ICD-10 ICD-10: G43, G43.9 ICD-9 ICD-9: 346 Expand ICD-9 346
Disease Identifiers	MONDO ID MONDO_0008000 MESH ID D008881 UMLS CUI C3887485 OMIM ID 157300 MedGen ID 854348 HPO ID HP:0002076 SNOMED CT ID 37796009

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 25 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Almogran	DM7I64Z	Approved	Small molecular drug	[1]
Amfepramone	DM9YSNQ	Approved	Small molecular drug	[2]
Atogepant	DMZGKXW	Approved	NA	[3]
Budipine	DMODHQI	Approved	Small molecular drug	[4]
Buprenorphine	DMPRI8G	Approved	Small molecular drug	[5]
Dihydroergotamine	DM5IKUF	Approved	Small molecular drug	[6]
Eletriptan	DMW649X	Approved	Small molecular drug	[7]
Eptinezumab	DM5LJCI	Approved	NA	[8]
Flunarizine	DMZU5JP	Approved	Small molecular drug	[9]
Frovatriptan	DM7RE8P	Approved	Small molecular drug	[10]
Ketoprofen	DMRKXPT	Approved	Small molecular drug	[11]
Lasmiditan	DMXLVDT	Approved	Small molecular drug	[12]
LOMERIZINE	DME0TC8	Approved	Small molecular drug	[13]
Lornoxicam	DMYZFXN	Approved	Small molecular drug	[13]
Methysergide	DM1EF73	Approved	Small molecular drug	[14]
Naratriptan	DMO50U2	Approved	Small molecular drug	[15]
Propranolol	DM79NTF	Approved	Small molecular drug	[16]
Rimegepant	DMHOAUG	Approved	Small molecular drug	[17]
Rizatriptan	DMDJMA3	Approved	Small molecular drug	[18]
Sumatriptan	DMVYXR8	Approved	Small molecular drug	[19]
Treximet	DMU54QB	Approved	Small molecular drug	[20]
Ubrogepant	DM749I3	Approved	Small molecular drug	[21]
Zavegepant	DMTROUI	Approved	Small molecular drug	[22]
Zolmitriptan	DM1IB4Q	Approved	Small molecular drug	[23]
LY2951742	DMP96JO	Phase 4	NA	[24]
------------------------------------------------------------------------------------


⏷ Show the Full List of 25 Drug(s)

This Disease is Treated as An Indication in 29 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
DFN-02	DM8FZAB	Phase 3	NA	[11]
DFN-15	DM3BF9B	Phase 3	NA	[11]
M207	DM2CLXU	Phase 3	NA	[11]
PH80-PMD	DMUJORY	Phase 3	NA	[25]
Recombinant botulinum neurotoxin vaccine	DM8I4HO	Phase 3	NA	[26]
TEV-48125	DMMTKC6	Phase 3	Antibody	[27]
AGS-003	DMMNLWI	Phase 2	NA	[28]
ALD-403	DM6RBYT	Phase 2	NA	[29]
ALLOD-2	DMCITS3	Phase 2	NA	[11]
AMG 301	DMO72IF	Phase 2	NA	[11]
AMG 334	DMI3WFG	Phase 2	NA	[30]
BGC-20-1531	DMS2MQ5	Phase 2	Small molecular drug	[31]
BI-44370	DMZR9OU	Phase 2	NA	[32]
Dorolac	DMVWZDB	Phase 2	NA	[11]
LY-2590443	DM81UJW	Phase 2	NA	[33]
LY-334370	DM43O9N	Phase 2	Small molecular drug	[34]
MK-3207	DM6OLGC	Phase 2	Small molecular drug	[35]
NXN-188	DMMBAIH	Phase 2	Small molecular drug	[36]
Olcegepant	DMVW5KR	Phase 2	Small molecular drug	[37]
SB-705498	DMRYHWI	Phase 2	Small molecular drug	[38]
Telcagepant	DMFT5D6	Phase 2	Small molecular drug	[39]
AMG 333	DMF9VNC	Phase 1	NA	[40]
BF-1	DM7RPSG	Phase 1	Small molecular drug	[41]
CVT-427	DMPYUWH	Phase 1	NA	[11]
INP104	DMVKPD8	Phase 1	NA	[11]
LBR-101	DM4YA0D	Phase 1	Antibody	[42]
PF-4427429	DM3427C	Phase 1	NA	[43]
TRV250	DM2WZ86	Phase 1	NA	[11]
XEN007	DMNKV3O	Phase 1	NA	[44]
------------------------------------------------------------------------------------


⏷ Show the Full List of 29 Drug(s)

This Disease is Treated as An Indication in 25 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Alniditan	DMFE3CT	Discontinued in Phase 3	Small molecular drug	[45]
Avitriptan	DM3SE2N	Discontinued in Phase 3	Small molecular drug	[46]
LLL-2011	DM5EQID	Discontinued in Phase 3	NA	[47]
4991W93	DMUXMGN	Discontinued in Phase 2	Small molecular drug	[48]
CP-122288	DM3OJP0	Discontinued in Phase 2	Small molecular drug	[49]
FK-888	DM457B1	Discontinued in Phase 2	Small molecular drug	[50]
GV-196771	DMFN21T	Discontinued in Phase 2	Small molecular drug	[51]
IS-159	DMLQWFA	Discontinued in Phase 2	Small molecular drug	[52]
LY-2300559	DMTS1X5	Discontinued in Phase 2	NA	[53]
PNU-142633	DMLK5IM	Discontinued in Phase 2	Small molecular drug	[54]
SERGOLEXOLE MALEATE	DM9KB8A	Discontinued in Phase 2	Small molecular drug	[55]
ALX-0646	DMNOZAI	Discontinued in Phase 1	Small molecular drug	[56]
GR-127607	DMRNI6K	Discontinued in Phase 1	NA	[57]
MT-500	DMCJ1B2	Discontinued in Phase 1	Small molecular drug	[58]
Tidembersat	DMTC4LP	Discontinued in Phase 1	Small molecular drug	[59]
ALX-0625	DM4PK3X	Terminated	NA	[63]
BMS-181885	DMYWI04	Terminated	NA	[64]
Dotarizine	DM6Q05K	Terminated	Small molecular drug	[65]
L-694247	DM2F4GT	Terminated	Small molecular drug	[66]
LY467711	DM0TV9L	Terminated	Small molecular drug	[67]
LY525327	DMPNMAR	Terminated	Small molecular drug	[67]
OX-641	DMP0F6O	Terminated	NA	[68]
PNU-109291	DMZNM2K	Terminated	Small molecular drug	[69]
SRSS-023	DMUGPDB	Terminated	NA	[70]
VR-147	DMLWQOP	Terminated	NA	[71]
------------------------------------------------------------------------------------


⏷ Show the Full List of 25 Drug(s)

This Disease is Treated as An Indication in 5 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Rizaport	DMG59CZ	Application submitted	NA	[11]
Semprana	DMBWI67	Application submitted	NA	[11]
BIO-306	DMPUBK8	Preclinical	Small molecular drug	[60]
Donitriptan	DMA2K7C	Preclinical	Small molecular drug	[61]
XP-20925	DMFNXNO	Preclinical	NA	[62]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 8 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ALGRX 2872	DM9Y5M5	Investigative	NA	[72]
BMS-694153	DM8PA3U	Investigative	Small molecular drug	[73]
CL-H01	DM74LLK	Investigative	NA	[72]
CWF-0902	DMEBZIG	Investigative	NA	[72]
ELS-110	DM8VKU0	Investigative	NA	[72]
MK-2918	DMDB1IQ	Investigative	NA	[72]
MystiTrip	DMVBSBF	Investigative	NA	[72]
XGP-310	DMTG604	Investigative	NA	[72]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 1 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ALPK1	OTBW6SGD	Strong	Genetic Variation	[74]
------------------------------------------------------------------------------------

References

1	Drug information of Almogran, 2008. eduDrugs.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7161).
3	FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 215206.
4	Multiple mechanisms of action: the pharmacological profile of budipine. J Neural Transm Suppl. 1999;56:83-105.
5	ClinicalTrials.gov (NCT00941304) Study of BEMA Buprenorphine in the Treatment of Dental Pain. U.S. National Institutes of Health.
6	Sustained pain relief with dihydroergotamine in migraine is potentially due to persistent binding to 5-HT1B and 5-HT1D receptors. . The Journal of Headache and Pain 201314(Suppl 1):P75.
7	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 40).
8	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
9	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 012102.
10	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7191).
11	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
12	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
13	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
14	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 134).
15	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 45).
16	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7596).
17	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
18	Clinical pipeline report, company report or official report of Intelgenx.
19	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 54).
20	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 021926.
21	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
22	FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 216386.
23	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 60).
24	ClinicalTrials.gov (NCT04294147) A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist. U.S. National Institutes of Health.
25	ClinicalTrials.gov (NCT01217775) Intranasal PH80 Spray for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder. U.S. National Institutes of Health.
26	ClinicalTrials.gov (NCT01940315) Phase 3, Randomized, Safety, Lot Consistency and Clinical Benefit Study of Recombinant Botulinum Vaccine A/B. U.S. National Institutes of Health.
27	ClinicalTrials.gov (NCT03303105) Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine. U.S. National Institutes of Health.
28	ClinicalTrials.gov (NCT01482949) A Rollover Protocol for Subjects Previously Treated With AGS-003. U.S. National Institutes of Health.
29	ClinicalTrials.gov (NCT02275117) A Multicenter Assessment of ALD403 in Chronic Migraine. U.S. National Institutes of Health.
30	ClinicalTrials.gov (NCT02174861) A Study to Assess the Long-term Safety and Efficacy of AMG 334 in Chronic Migraine Prevention.. U.S. National Institutes of Health.
31	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3380).
32	ClinicalTrials.gov (NCT00751803) BI 44370 TA in Acute Migraine Attack. U.S. National Institutes of Health.
33	ClinicalTrials.gov (NCT00804973) Study in Subjects With Acute Migraines Headaches.. U.S. National Institutes of Health.
34	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 20).
35	ClinicalTrials.gov (NCT00712725) MK3207 for Treatment of Acute Migraines (3207-005). U.S. National Institutes of Health.
36	ClinicalTrials.gov (NCT00920686) Study of NXN 188 for the Treatment of Migraine With Aura. U.S. National Institutes of Health.
37	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 702).
38	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4311).
39	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 703).
40	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039038)
41	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8424).
42	Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program. Cephalalgia. 2013 Dec 23;34(7):483-492.
43	ClinicalTrials.gov (NCT01117233) Study In Healthy Adult Volunteers To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429. U.S. National Institutes of Health.
44	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
45	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 120).
46	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002927)
47	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027219)
48	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009029)
49	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 110).
50	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2114).
51	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4208).
52	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005786)
53	ClinicalTrials.gov (NCT01184508) A Study in Migraine Prevention. U.S. National Institutes of Health.
54	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013927)
55	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000706)
56	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008400)
57	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003531)
58	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013923)
59	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010348)
60	Pharmacologic therapeutics for cardiac reperfusion injury. Expert Opin Emerg Drugs. 2007 Sep;12(3):367-88.
61	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 39).
62	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023507)
63	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008398)
64	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007062)
65	Vasostabilizing effect of Dotarizine (Ca(2+)-channel blocker) on cerebrovascular reactivity in rabbits. Neurol Res. 2000 Mar;22(2):229-32.
66	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 15).
67	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015556)
68	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022464)
69	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3228).
70	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019089)
71	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023937)
72	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
73	Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan... J Med Chem. 2008 Aug 28;51(16):4858-61.
74	ALPK1 missense pathogenic variant in five families leads to ROSAH syndrome, an ocular multisystem autosomal dominant disorder. Genet Med. 2019 Sep;21(9):2103-2115. doi: 10.1038/s41436-019-0476-3. Epub 2019 Apr 10.